Meeting Banner
Abstract #3298

Longitudinal changes in diffusion basis spectrum imaging metrics of normal-appearing white matter and lesions in ocrelizumab-treated relapsing multiple sclerosis

Anika Wurl1,2, Irene M Vavasour3, Adam Dvorak4,5, Nathalie Ackermans1, Cornelia Laule3,4,5,6, David KB Li3, Robert Carruthers1, Alex L Mackay3,4, Roger Tam3,7, Anne H Cross8, Peng Sun8, Sheng-Kwei Song8, Hideki Garren9, Anthony Traboulsee1, and Shannon H Kolind1,4,5

1Medicine, University of British Columbia, Vancouver, BC, Canada, 2Physics, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany, 3Radiology, University of British Columbia, Vancouver, BC, Canada, 4Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada, 5International Cooperation on Repair Discoveries (ICORD), University of British Columbia, Vancouver, BC, Canada, 6Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, 7School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada, 8School of Medicine, Washington University, St. Louis, MO, United States, 9Genentech, Inc., South San Francisco, CA, United States

Diffusion Basis Spectrum Imaging (DBSI) probes axonal and myelin damage by modeling the diffusion-weighted MRI signal as discrete anisotropic diffusion tensors while simultaneously differentiating and quantifying inflammation and edema through a modeled isotropic diffusion tensor spectrum. We studied 15 RMS patients beginning ocrelizumab treatment over two years as well as 10 healthy controls.

DBSI detected microstructural differences between RMS normal-appearing white matter, chronic and enhancing lesions, and healthy control white matter. Further, the metrics were sensitive to changes within two years of follow-up and showed improvement towards healthy control values in patients treated with ocrelizumab.

This abstract and the presentation materials are available to members only; a login is required.

Join Here